Infectious Disease

Infectious diseases include viruses, bacteria, parasites, fungi, protozoa and prions. Surveys and online discussions in this area cover subjects such as current and emerging therapies for hepatitis C; evaluation of Oritavancin, and drugs being developed against Methicillin-Resistant Staphylococcus Aureus (MRSA).
Reports become free one year after publication date.

 

Report Name	Report Type	Specialty	Publish Date
HIV Therapies in the EU:  Gauging the potential of Atripla	Survey	Infectious Disease	May 21, 2008	FREE
To understand current practices regarding the use of HIV therapies in the EU and to assess the market potential of Atripla. Determine current practice patterns in HIV. Quantify usage and market potential of agents in HIV patients. Gain...
Selzentry (Maraviroc) HIV Treatment	Discussion	Infectious Disease	Apr 16, 2008	FREE
To conduct a panel among HIV specialists to better understand changes in physicians’ treatment regimens and prescription patterns since Selzentry ™ (maraviroc) was released on August 6, 2007. Understand the market size and patient population that uses maraviroc ...
Targanta Therapeutics IPO Panel	Discussion	Infectious Disease	Oct 4, 2007	FREE
Panel Intelligence engaged a panel of nine key opinion leaders in infectious disease to discuss Oritavancin, the primary drug in development by Targanta Therapeutics. Topics to be discussed include: Clinical opinions about Oritavancin and its potential therapeutic...
ICAAC 2007 Leadership Summit	Discussion	Infectious Disease	Sep 14, 2007	FREE
To discuss the latest research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) with key opinion leaders in the field of infectious disease. ICAAC was held in Chicago from September 17-20, 2007. Review drugs being developed...
Hepatitis C: Current and Emerging Therapies	Discussion	Infectious Disease	Apr 24, 2007	FREE
Panel Intelligence engaged a group of hepatologists in an online, interactive discussion designed to: Examine ITMN-191’s strengths and weaknesses Gauge ITMN-191’s strengths and weaknesses in comparison to other promising agents in development, including: ...

 

 

about us       contact us

© MedPanel, LLC. 1999-2010. All rights reserved. Privacy Policy